In vivo delivery of antisense morf oligomer by morf/carrier streptavidin nanoparticles

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 5, 2009, Pages 573-578

  Wang, Yi ^a   Liu, Xinrong ^a   Nakamura, Kayoko ^b   Chen, Ling ^a   Rusckowski, Mary ^a   Hnatowich, Donald J ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antisense; MORF; Nanoparticle; Streptavidin

Indexed keywords

OLIGOMER; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; POLYARGININE; STREPTAVIDIN; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISENSE VECTOR; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; BIOTINYLATION; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MORPHOLINES; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDES; STREPTAVIDIN; TECHNETIUM;

EID: 70449122990     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0624     Document Type: Article

References (29)

1. Sahu NK, Shilakari G, Nayak A, et al. Antisense technology: A selective tool for gene expression regulation and gene targeting. Curr Pharm Biotechnol 2007;8:291.
2. Chan JH, Lim S, Wong WS. Antisense oligonucleotides: From design to therapeutic application. Clin Exp Pharmacol Physiol 2006;33:533.
3. Wang Y, Nakamura K, Liu X, Kitamura N, Kubo A, Hnatowich DJ. Simplified preparation via streptavidin of antisense oligomers=carriers nanoparticles showing improved cellular delivery in culture. Bioconj Chem 2007;18:1338.
4. Liu X, Wang Y, Nakamura K, et al. Cell studies of a threecomponent antisense MORF=tat=herceptin nanoparticle designed for improved tumor delivery. Cancer Gene Ther 2008;15:126.
5. Nakamura K, Wang Y, Liu X, et al. Cell culture and xenografted animal studies of radiolabeled antisense DNA= carrier nanoparticles using streptavidin as linker. J Nucl Med 2007;48:1845.
6. Brown DA, Kang SH, Gryaznov SM, et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994;269:26801.
7. Hawley P, Nelson JS, Fearon KL, et al. Comparison of binding of N30- >P50 phosphoramidate and phosphorothioate oligonucleotides to cell surface proteins of cultured cells. Antisense Nucleic Acid Drug Dev 1999;9:61.
8. Temsamani J, Roskey A, Chaix C, et al. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide. Antisense Nucleic Acid Drug Dev 1997;7:159.
9. Summerton J, Stein D, Huang SB, et al. Morpholino and phosphorothioate antisense oligomers compared in cell-free and incell systems. Antisense Nucleic Acid Drug Dev 1997;7:63.
10. Summerton J, Weller D. Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997;7:187.
11. Hudziak RM, Barofsky E, Barofsky DF, et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev 1996;6:267.
12. Gebski BL, Mann CJ, Fletcher S, et al. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 2003;12:1801.
13. Brent LJ, Drapeau P. Targeted ''knockdown'' of channel expression in vivo with an antisense morpholino oligonucleotide. Neuroscience 2002;114:275.
14. Zhang Y, Wang Y, Liu N, et al. In vitro investigations of tumor targeting with 99mTc-labeled antisense DNA. J Nucl Med 2001;42:1660.
15. Winnard P, Jr, Chang F, Rusckowski M, et al. Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. Nucl Med Biol 1997;24:425.
16. Wang Y, Liu X, Hnatowich DJ. An improved synthesis of NHS-MAG3 for conjugation and radiolabeling of biomolecules with 99mTc at room temperature. Nat Protoc 2007;2:972.
17. Wang Y, Liu G, Hnatowich DJ. Methods for MAG3 conjugation and 99mTc radiolabeling of biomolecules. Nat Protoc 2006;1:1477.
18. Zhang Y, He J, Liu G, et al. Initial observations of 99mTc-labelled locked nucleic acids for antisense targeting. Nucl Med Commun 2004;25:1113.
19. Nakamura K, Fan C, Liu G, et al. Evidence of antisense tumor targeting in mice. Bioconj Chem 2004;15:1475.
20. Nakamura K, Wang Y, Liu X, et al. Influence of two transfectors on delivery of 99mTc antisense DNA in tumor-bearing mice. Mol Imaging Biol 2006;8:188.
21. Liu X, Wang Y, Nakamura K, et al. Optical antisense imaging of tumor with fluorescent DNA duplexes. Bioconj Chem 2007;18:1905.
22. Hnatowich DJ, Nakamura K. The influence of chemical structure of DNA and other oligomer radiopharmaceuticals on tumor delivery. Curr Opin Mol Ther 2006;8:136.
23. Wang Y, Liu X, Nakamura K, et al. The accumulation of antisense MORF is improved when linked to internalizing antibodies via streptavidin and with evidence of release [abstract]. Abstr Book Joint Mol Imaging Confer Acad Mol Imaging Soc Mol Imaging 2007;313P.
24. Liu G, He J, Zhang S, et al. Cytosine residues influence kidney accumulations of 99mTc-labeled morpholino oligomers. Antisense Nucleic Acid Drug Dev 2002;12:393.
25. Sinko PJ, Martin AN. Martin's Physical Pharmacy and Pharmaceutical Sciences, 5th ed. Philadelphia: Lippincott Wilkins & Wilkins, 2005:388.
26. Liu G, He J, Dou S, et al. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging 2004;31:417.
27. Ngai WM, Reilly RM, Polihronis J, et al. In vitro and in vivo evaluation of streptavidin immunoconjugates of the second generation TAG-72 monoclonal antibody CC49. Nucl Med Biol 1995;22:77.
28. Zhang M, Sakahara H, Yao Z, et al. Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody. Nucl Med Biol 1997;24:61.
29. Wilbur DS, Hamlin DK, Buhler KR, et al. Streptavidin in antibody pretargeting. 2. Evaluation of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity. Bioconj Chem 1998;9:322.